Modern Antidepressants: A Comparative Analysis of Efficacy, and Safety, and Prospects for Studying New Drugs



Cite item

Full Text

Abstract

The article provides a review of modern scientific publications on the use of antidepressants with various mechanisms of action, considers the most frequently used drugs in clinical practice, their mechanism of action, tolerability profile, and drug safety. Approaches to choosing an antidepressant, considering the underlying disease and comorbidities, are examined. Data on the study of new alternative drugs with antidepressant action are presented. When choosing an antidepressant, it is necessary to consider the complexity and multifactorial nature of the clinical picture of each patient, requiring a strictly individualized approach. For rational therapy and optimization of clinical results, a deep understanding of the mechanisms of action, indications, potential side effects, and pharmacokinetic features of various classes of antidepressants is necessary. The emergence of drugs with a multimodal mechanism of action expands the possibilities for personalization of therapy, increasing the effectiveness of treatment not only for depressive and anxiety disorders but also for depressive syndrome occurring in somatic and neurological diseases. Further research on pharmacogenetic factors and the development of personalized approaches to the selection of antidepressants will open up new opportunities for improving therapy and improving the quality of life for patients.

About the authors

Tatiana A. Pavlova

City Clinic Medical Center

Email: pava-6@yandex.ru

Candidate of Medical Sciences, Psychiatrist

Russian Federation, Москва

Marina A. Telepina

Saint Petersburg State Chemical and Pharmaceutical University

Email: marina.telepina@spcpu.ru

Student, Faculty of Industrial Drug Technology

Russian Federation, Санкт-Петербург

Vladimir V. Perelygin

Saint Petersburg State Chemical and Pharmaceutical University

Email: vladimir.pereligin@pharminnotech.com
ORCID iD: 0000-0002-0999-5644
SPIN-code: 3128-7451
Scopus Author ID: 13105602000
ResearcherId: AAV-6556-2020

Dr. Med. Sci., Professor, Head of the Industrial Ecology Department

Russian Federation, Saint Petersburg

Ekaterina A. Smetannikova

Psychoneurological Dispensary No. 10

Email: prof@pnd10spb.ru

Psychiatrist, Child Psychiatrist

Russian Federation, Санкт-Петербург

Natalia A. Sklyarova

Saint Petersburg State Chemical and Pharmaceutical University

Email: natalia.sklyarova@pharminnotech.com

Candidate of Technical Sciences, Associate Professor of the Department of Industrial Ecology

Russian Federation, Saint Petersburg

Anastasia V. Orlova

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: vao608@yandex.ru

Clinical Resident, Department of Psychiatry, Institute of Continuing Education and Professional Development

Russian Federation, Москва

References

  1. World Health Organization. Depression [Elektronnyi resurs]. 2023. URL: https://www.who.int/news-room/fact-sheets/detail/depression. (data obrashcheniya 07.06.2025).
  2. National Institute of Mental Health. Major Depression [Elektronnyi resurs]. 2023. URL: https://www.nimh.nih.gov/health/statistics/major-depression. (data obrashcheniya 07.06.2025).
  3. European Agency for Safety and Health at Work. Mental health at work [Elektronnyi resurs]. 2023. URL: https://osha.europa.eu/en/themes/mental-health. (data obrashcheniya 07.06.2025).
  4. Braslow J.T., Marder S.R.. History of Psychopharmacology. Annu Rev Clin Psychol. 2019 May 7;15:25–50. doi: 10.1146/annurev-clinpsy-050718-095514. Epub 2019 Feb 20.
  5. Gillman, P. K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated // British Journal of Pharmacology. 2007. Vol. 151, no. 6. P. 737–748. doi: 10.1038/sj.bjp.0707253.
  6. Ye. N., Wang Q., Li. Y., Zhen X. Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities. Med Res Rev. 2025 Mar;45(2):755-787. doi: 10.1002/med.22086.
  7. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M.; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23;354(12):1231-42. doi: 10.1056/NEJMoa052963.
  8. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx) // Institute of Health Metrics and Evaluation. URL: (data obrashcheniya 07.06.2025).
  9. Nestler, E. J., et al. "Neurobiology of depression". Neuron 34.6 (2002): 865–881. doi: 10.1016/S0896-6273(02)00653-0.
  10. Krogh, J., et al. "The inflammatory and oxidative stress hypothesis of depression: A meta-analysis of randomized controlled trials". Journal of Clinical Psychiatry 79.6 (2018): e1-e10.
  11. Stahl, S. M. "Mechanism of action of vortioxetine: the first multimodal antidepressant". CNS Spectrums 20.2 (2015): 96–101.
  12. Depression in neurological practice: use of antidepressants / R. F. Abdurakhmanova, H. N. Izzatov, G. R. Khadibaeva [et al.] // Bulletin of postgraduate education in health care. – 2015. – No. 4. – P. 55–63. (In Russ).
  13. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov // RMZh. 2005. T. 13, № 12. S. 852–57. (In Russ).
  14. Tabeeva, G. R. Cognitive disorders in depression and new targets of therapy / G. R. Tabeeva // Effective pharmacotherapy. – 2018. – No. 20. – P. 28–37. (In Russ).
  15. Shuteeva, T. V. Treatment of depressive disorders in Parkinson's disease / T. V. Shuteeva, E. A. Logacheva // Effective clinical practice: problems and possibilities of a modern doctor: Collection of materials of the international scientific and practical conference, Kursk, May 12, 2017 / Edited by N. K. Gorshunova. – Kursk: Kursk State Medical University, 2017. – P. 500–507. (In Russ).
  16. Kotov A. S., Firsov K. V., Kotova T. S. Komorbidnost' u patsientov s epilepsiei. Moskva: Izdatel'skie resheniya, 2025. 280 s. ISBN: 978-5-0065-8751-9. (In Russ).
  17. Sadovnichuk E. A. Multiple sclerosis: mechanisms of neurodegeneration and instrumentally detectable markers of neurodegeneration (literature review) / E. A. Sadovnichuk, M. P. Topuzova, V. A. Malko [et al.] // Russian Neurosurgical Journal named after Professor A.L. Polenov. – 2023. – Vol. 15, No. 3. – P. 158–163. – doi: 10.56618/2071-2693_2023_15_3_158. (In Russ).
  18. Voronova, E. I. Reactive (psychogenic) depressions / E. I. Voronova, E. B. Dubnitskaya // Journal of Neurology and Psychiatry named after S. S. Korsakov. – 2015. – Vol. 115, No. 2. – P. 75–85. – doi: 10.17116/jnevro20151152175-85. (In Russ).
  19. Scheidegger J.M., Dorovskiкh I.V., Pavlova T.A. Pathogenetic mechanisms of antinociceptive activity of antidepressants // Pharmacy Formulas. – 2020. – Vol. 2. – N. 2. – P. 70–83. doi: 10.17816/phf34802. (In Russ).
  20. Stahl, S. M. (2018). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  21. Wong, M. L., & Kulkarni, S. K. (2008). Serotonin 1A receptors as targets for treatment of mood disorders. CNS Drugs, 22(12), 1015–1035.
  22. Ferguson J.M. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2001 Feb;3(1):22–27. doi: 10.4088/pcc.v03n0105.
  23. Zoloft (sertraline hydrochloride) prescribing information. Pfizer Inc.
  24. Foster, R.H., Goa, K.L. Paroxetine. CNS Drugs 8, 163–188 (1997). https://doi.org/10.2165/00023210-199708020-00010
  25. Paxil (paroxetine hydrochloride) prescribing information. GlaxoSmithKline.
  26. Luvox (fluvoxamine maleate) prescribing information. Solvay Pharmaceuticals, Inc.
  27. MotherToBaby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Citalopram | Escitalopram (Celexa® | Lexapro®). 2023 Jan.
  28. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013 Jan;137(1):119–31. doi: 10.1016/j.pharmthera.2012.09.006. Epub 2012 Sep 26.
  29. Khan A., Fabre L.F., Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull. 1991;27(2):141–4.
  30. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002 Apr;63(4):308–15. doi: 10.4088/jcp.v63n0407.
  31. Richelson E. Pharmacology of antidepressants. Psychopathology. 1987;20 Suppl 1:1–12. doi: 10.1159/000284517.
  32. Dan G. Blazer. The American Psychiatric Press Textbook of Psychopharmacology (Second Edition): by AF Schatzberg, CB Nemeroff (eds.), Washington, DC: American Psychiatric Press, 1998
  33. Fagiolini A., González-Pinto A., Miskowiak K.W., Morgado P., Young A.H., Vieta E. Role of trazodone in treatment of major depressive disorder: an update. Ann Gen Psychiatry. 2023 Sep 2;22(1):32. doi: 10.1186/s12991-023-00465-y.
  34. Holm K.J., Markham A.. Mirtazapine: a review of its use in major depression. Drugs. 1999 Apr;57(4):607–31. doi: 10.2165/00003495-199957040-00010.
  35. Serretti A. Anhedonia and Depressive Disorders. Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):401–409. doi: 10.9758/cpn.23.1086.
  36. McIntyre R.S., Harrison J., Loft H., Jacobson W., Olsen C.K. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016 Jun 15;19(10):pyw055. doi: 10.1093/ijnp/pyw055.
  37. Sunyakov, T. S. Anxiolytics / T. S. Sunyakov // Psychiatry and psychopharmacotherapy. – 2021. – Vol. 23, No. 4. – P. 9–20. (In Russ).
  38. Rönnbäck, L., Hansson, E. On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 1 , 22 (2004). https://doi.org/10.1186/1742-2094-1-22
  39. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008 May;7(5):426–37. doi: 10.1038/nrd2462.
  40. Bykov Yu.V., Baturin V.A. Glutamatergic system dysfunction in the pathophysiology of diabetic encephalopathy. Pacific Medical Journal. 2023;(3):15-19. (In Russ.) https://doi.org/10.34215/1609-1175-2023-3-15-19. (In Russ).
  41. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856.
  42. Daly E.J., Singh J.B., Fedgchin M., Cooper K., Lim P., Shelton R.C., Thase M.E., Winokur A., Van Nueten L., Manji H., Drevets W.C. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018 Feb 1;75(2):139–148. doi: 10.1001/jamapsychiatry.2017.3739.
  43. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010 Aug 20;329(5994):959-64. doi: 10.1126/science.1190287.
  44. Nakanishi S., Nakajima Y., Masu M., Ueda Y., Nakahara K., Watanabe D., Yamaguchi S., Kawabata S., Okada M. Glutamate receptors: brain function and signal transduction. Brain Res Brain Res Rev. 1998 May;26(2–3):230–5. doi: 10.1016/s0165-0173(97)00033-7.
  45. Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry. 2013 Jun 15;73(12):1172–9. doi: 10.1016/j.biopsych.2013.03.032.
  46. Dogra S., Conn P.J. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders. Neuropharmacology. 2021 Sep 15;196:108687. doi: 10.1016/j.neuropharm.2021.108687.
  47. Wierońska J.M., Zorn S.H., Doller D., Pilc A. Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. Pharmacol Ther. 2016 Jan;157:10–27. doi: 10.1016/j.pharmthera.2015.10.007.
  48. Li M.L., Hu X.Q., Li F., Gao W.J. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end? Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:66–76. doi: 10.1016/j.pnpbp.2015.02.012.
  49. Zhou Y., Danbolt N.C. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014 Aug;121(8):799–817. doi: 10.1007/s00702-014-1180-8.
  50. Brites D., Fernandes A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci. 2015 Dec 17;9:476. doi: 10.3389/fncel.2015.00476.
  51. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56. doi: 10.1038/nrn2297.
  52. Björkholm C., Monteggia L.M. BDNF - a key transducer of antidepressant effects. Neuropharmacology. 2016 Mar;102:72–9. doi: 10.1016/j.neuropharm.2015.10.034.
  53. Simon M.S., Arteaga-Henríquez G., Fouad Algendy A., Siepmann T., Illigens BMW. Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses. Neuropsychiatr Dis Treat. 2023 Jan 5;19:1–25. doi: 10.2147/NDT.S385117.
  54. Miller A.H., Raison C.L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016 Jan;16(1):22–34. doi: 10.1038/nri.2015.5.
  55. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013 Jan;70(1):31–41. doi: 10.1001/2013.jamapsychiatry.4.
  56. Шилов Юрий Евгеньевич, Безруков Михаил Васильевич Кинуренины в патогенезе эндогенных психических заболеваний // Вестник РАМН. 2013. №1. URL: https://cyberleninka.ru/article/n/kinureniny-v-patogeneze-endogennyh-psihicheskih-zabolevaniy (дата обращения: 10.07.2025).
  57. Schwarcz, R., Bruno, J., Muchowski, P. et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13, 465–477 (2012). https://doi.org/10.1038/nrn3257.
  58. Venkatesan D., Iyer M., Narayanasamy A., Siva K., Vellingiri B.. Kynurenine pathway in Parkinson's disease-An update. eNeurologicalSci. 2020 Sep 10;21:100270. doi: 10.1016/j.ensci.2020.100270.
  59. Hökfelt T. Neuropeptides in perspective: the last ten years. Neuron. 1991 Dec;7(6):867–79. doi: 10.1016/0896-6273(91)90333-u.
  60. Skryabin V., Rozochkin I., Zastrozhin M., Lauschke V., Franck J., Bryun E., Sychev D. Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder. Pharmacogenomics J. 2023 May;23(2-3):45–49. doi: 10.1038/s41397-022-00295-3.
  61. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NM. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998 Sep 11;281(5383):1640–5. doi: 10.1126/science.281.5383.
  62. Messina A., De Fusco C., Monda V., Esposito M., Moscatelli F., Valenzano A., Carotenuto M., Viggiano E., Chieffi S., De Luca V., Cibelli G., Monda M., Messina G. Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis. Front Neural Circuits. 2016 Aug 25;10:66. doi: 10.3389/fncir.2016.00066.
  63. Saitoh T., Sakurai T. The present and future of synthetic orexin receptor agonists. Peptides. 2023 Sep;167:171051. doi: 10.1016/j.peptides.2023.171051.
  64. Yue J.L., Chang X.W., Zheng J.W., Shi L., Xiang Y.J., Que J.Y., Yuan K., Deng J.H., Teng T., Li Y.Y., Sun W., Sun H.Q., Vitiello M.V., Tang X.D., Zhou X.Y., Bao Y.P., Shi J., Lu L. Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis. Sleep Med Rev. 2023 Apr;68:101746. doi: 10.1016/j.smrv.2023.101746.
  65. Cryan J.F., O'Riordan K.J., Cowan C.S.M., Sandhu K.V., Bastiaanssen T.F.S., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., Guzzetta K.E., Jaggar M., Long-Smith C.M., Lyte J.M., Martin J.A., Molinero-Perez A., Moloney G., Morelli E., Morillas E., O'Connor R., Cruz-Pereira J.S, Peterson V.L., Rea K., Ritz N.L., Sherwin E., Spichak S., Teichman E.M., van de Wouw M., Ventura-Silva A.P., Wallace-Fitzsimons S.E., Hyland N., Clarke G., Dinan T.G. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019 Oct 1;99(4):1877–2013. doi: 10.1152/physrev.00018.2018.
  66. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018 Aug 15;1693(Pt B):128–133. doi: 10.1016/j.brainres.2018.03.015.
  67. Collins S.M., Surette M., Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012 Nov;10(11):735-42. doi: 10.1038/nrmicro2876.
  68. Wolf G. Gut microbiota: a factor in energy regulation. Nutr Rev. 2006 Jan;64(1):47–50. doi: 10.1111/j.1753-4887.2006.tb00173.x.
  69. Bäckhed F., Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718–23. doi: 10.1073/pnas.0407076101.
  70. Mariat D., Firmesse O., Levenez F., Guimarăes V., Sokol H., Doré J., Corthier G., Furet J.P. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009 Jun 9;9:123. doi: 10.1186/1471-2180-9-123.
  71. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. Erratum in: Ann Gen Psychiatry. 2017 Mar 7;16:18. doi: 10.1186/s12991-017-0141-7.
  72. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., Visser C.E., Kuijper E.J., Bartelsman J.F., Tijssen J.G., Speelman P., Dijkgraaf M.G., Keller J.J. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407–15. doi: 10.1056/NEJMoa1205037.
  73. Conover K.R., Absah I., Ballal S., Brumbaugh D., Cho S., Cardenas M.C., Knackstedt E.D., Goyal A., Jensen M.K., Kaplan J.L., Kellermayer R., Kociolek L.K., Michail S., Oliva-Hemker M., Reed A.W., Weatherly M., Kahn S.A., Nicholson M.R.. Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients. J Pediatr Gastroenterol Nutr. 2023 Apr 1;76(4):440–446. doi: 10.1097/MPG.0000000000003714.
  74. Meng Y., Sun J., Zhang G.. Pick fecal microbiota transplantation to enhance therapy for major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Jan 10;128:110860. doi: 10.1016/j.pnpbp.2023.110860.
  75. Carhart-Harris R.L., Roseman L., Bolstridge M., Demetriou L., Pannekoek J.N., Wall M.B., Tanner M., Kaelen M., McGonigle J., Murphy K., Leech R., Curran H.V., Nutt D.J. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017 Oct 13;7(1):13187. doi: 10.1038/s41598-017-13282-7.
  76. Ross S., Bossis A., Guss J., Agin-Liebes G., Malone T., Cohen B., Mennenga S.E., Belser A., Kalliontzi K., Babb J., Su Z., Corby P., Schmidt B.L. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512. 77. Nutt D., Erritzoe D., Carhart-Harris R. Psychedelic Psychiatry's Brave New World. Cell. 2020 Apr 2;181(1):24–28. doi: 10.1016/j.cell.2020.03.020.
  77. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., Sanislow C., Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010 Jul;167(7):748–51. doi: 10.1176/appi.ajp.2010.09091379.
  78. Pan Z., Park C., Brietzke E., Zuckerman H., Rong C., Mansur R.B., Fus D., Subramaniapillai M., Lee Y., McIntyre R.S. Cognitive impairment in major depressive disorder. CNS Spectr. 2019 Feb;24(1):22–29. doi: 10.1017/S1092852918001207.
  79. Fabbri C., Marsano A., Serretti A. Genetics of serotonin receptors and depression: state of the art. Curr Drug Targets. 2013 May 1;14(5):531–48. doi: 10.2174/1389450111314050004.
  80. Greden J.F., Parikh S.V., Rothschild A.J., Thase M.E., Dunlop B.W., DeBattista C., Conway C.R., Forester B.P., Mondimore F.M., Shelton R.C., Macaluso M., Li J., Brown K., Gilbert A., Burns L., Jablonski M.R., Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 Apr;111:59–67. doi: 10.1016/j.jpsychires.2019.01.003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 76969 от 11.10.2019.